MSD total service package silver for CCD camera
Closed Solicitation Posted
- Solicitation number
- NOI-NIAID-25-2257361
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 811210 Electronic and Precision Equipment Repair and Maintenance
- Place of performance
- Bethesda, Maryland 20892, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health intends to negotiate a sole-source contract with Meso Scale Diagnostics for a Total Service Package Silver for CCD Camera. The procurement is focused on supporting the Vaccine Research Center's B Cell Immunology Section in developing monoclonal antibodies and vaccines for infectious diseases, with a particular emphasis on COVID-19 research. The contract aims to leverage an electrochemiluminescent (ECL) assay format for detecting antibodies specific to SARS-CoV-2 spike proteins and its variants, enabling high-throughput measurement of immune responses. Interested vendors must submit capabilities statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by May 1, 2025, at 12:00 pm EST. The statutory authority for this sole-source requirement is 41 U.S.C. 1901(a)(1), with the justification that only one responsible source can satisfy agency requirements.
The solicitation does not include any specific set-aside designations and is open to all responsible sources that can provide comparable services. The place of performance is located in Bethesda, MD 20892, and the contract falls under the NAICS category of Electronic and Precision Equipment Repair and Maintenance (NAICS 811210). While no specific award value is mentioned, the procurement is categorized under the PSC category of Maintenance/Repair/Rebuild of Instruments and Laboratory Equipment. The contract is specifically aimed at supporting ongoing COVID-19 research efforts, with a focus on developing assays for detecting antibodies to spike protein subdomains like RBD, NTD, S1, and S2. The work is critical for addressing the ongoing threat of COVID-19 and the emergence of new variants, with the goal of accelerating the development of monoclonal antibody therapies.
Notice text
This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate an other than full and open competition basis with Meso Scale Diagnostics for a Total Service Package Silver for CCD Camera.
The B Cell Immunology Section aids the Vaccine Research Center (VRC) by supporting the development of monoclonal antibodies and vaccines for infectious diseases such as HIV, Influenza, Ebola, and more recently SARS-CoV-2 Coronavirus. Support is through the state-of-the-art laboratory performing Phase 1 and Phase 3 clinical end point testing to inform further study designs, research questions and vaccine modification and design. As part of a broader strategy to accelerate the development of monoclonal antibodies as therapy for targeting SARS CoV-2 spike and its newly emerging variants, VIP has identified the electrochemiluminescent (ECL) assay format as the most reliable and sensitive assay system that offers high dynamic range in the detection of antibodies isolated specific to SARS-CoV-2 spike (S2P). Specifically, the VIP is in the process of developing an assay for detection of binding antibodies to subdomains of the spike such as RBD, NTD, S1 and S2, which offers high throughput measurement of immune responses elicited by infections.
As the threat of COVID-19 continues in the international community with new variants emerging every week, the need for a safe and efficacious monoclonal antibody therapy at an accelerated timeline is a health care priority. To assist in this effort, the VRC-VIP will use the electrochemiluminescent (ECL) assay format which they have recently developed for a SARS CoV-2 specific assay for the detection of specific antibodies directed towards SARS CoV-2 S-2P and RBD (or other stabilized version of this same protein), variants and subvariants (B.1.1.529, B.1.351, B.1.617). Spike proteins are 'printed' or 'spotted' in a single well of a MSD 96- well microtiter plate. The VRC-VIP identified the ECL assay as the most reliable and sensitive assay system over the last 10 years, that offers high dynamic range in the detection of specific serum antibodies generate towards a variety of viral proteins. The platform offers extremely high throughput for the simultaneous measurement of antibodies to their epitopes.
Capabilities statements must address the capability of providing a priority response equal to a direct contract/service agreement with the manufacturer.
The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capabilities statement that will be considered. The documents must be submitted via the NIAID electronic Simplified Acquisition Submission System (eSASS) website at https://esass.nih.gov, (subject line to reference NOI-NIAID-25-2257361 by May 1, 2025, by 12:00 pm eastern standard time. All vendors must register in the eSASS system to submit a capabilities statement. Instructions on how to register / submit quotes are included on the website. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responsible sources may submit a capabilities statement that will be considered by this Agency.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity